

[377] THE NEXT GENERATION OF FUNDUS CAMERAS

Udi Gordon¹, ¹ Camereyes

- **Investment Rational**

Camereyes has developed a disruptive, compact, fully automated non-mydratic fundus camera which captures high quality retinal images within 30 seconds, without a need for a skilled operator or a special setup.

The company has successfully demonstrated its camera to potential partners in Israel, USA, India and China and is looking to get regulatory approval and clinical validation in 6-12 months.
- **Business Strategy**

Our Camera ease of use and the low cost of ownership makes it ideal for use by care providers anywhere around the world. Thus, allowing simple and cost effective solution for screening and monitoring of diabetic retinopathy, hypertension etc.
- **Core Technology**

Camereyes' patent pending technology allows miniaturization of conventional fundus cameras while maintaining the same annular illumination method which allows high quality non-mydratic imaging. The compact form of the camera made it possible to integrate the camera into a goggle based headset with 3-dimensional positioning mechanism, eliminating the need for an operator or a bulky setup.
- **Product Profile/Pipeline**

Camereyes plans to launch its solution to the market during the first half of 2019. During that time, the company plans to achieve CE/FDA approvals and complete the clinical study, while making all necessary preparations for volume manufacturing of its product.

The company is discussing potential collaboration with number of companies who developed AI solution for automatic analysis of retinal images.
- **What's Next?**

Complete design for manufacturing and achieve regulatory approvals. Complete clinical study which demonstrate our camera capability to automatically capture quality retinal images.

The company is in the process fund raising to finance the above activities and get the product to the market with initial sales.